Pilot Study to Evaluate if Contrast Enhanced Ultrasound (CEUS) Can Predict Treatment Response in Triple Negative Breast Cancer (TNBC) Patients Receiving Combined Chemotherapy and Immune Checkpoint Inhibitors (ICI).

Summary

To find out if contrast enhanced ultrasound (CEUS) can be used to determine if patients receiving combined ICI therapy for triple negative breast cancer (TNBC) are responding to treatment earlier than standard of care MR or CT.

Timeline

Start

2023-09-01

Primary completion

2026-09-01

Completion

2031-09-01

Outcome

Outcome not reported

Stopped: “Responsible Party left the institution and the study will not be started by other investigator”

Drugs

Indications